The candidate research focuses on understanding the mechanisms of hematopoietic cell transformation, clonal evolution, and resistance using a combination of genomics and functional studies. The candidate has a strong track-record in genomics with several high impact papers and she had a leading role in The Pediatric Cancer Genome Project (Nature Genetics, 2015, cited 501). In 2012, she returned to Lund, to start a highly competitive research program with a strong focus on genomics.
Anna Hagström
Lund University
Keywords
Key Publications
Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in <i>KMT2A</i>-rearranged acute leukemia.
HemaSphere, 2024
Precision Diagnostics in Myeloid Malignancies: Development and Validation of a National Capture-Based Gene Panel.
Genes, chromosomes & cancer, 2024
Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia.
Genome biology, 2024
SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia.
Scientific reports, 2024
Molecular basis for human aquaporin inhibition.
Proceedings of the National Academy of Sciences of the United States of America, 2024